Zacharoula Sidiropoulou/researchgate.ne
May 22, 2025, 17:38
Zacharoula Sidiropoulou: Are the Treatments We Prescribe to Our Most Vulnerable Patients Actually Tested On Them?
Zacharoula Sidiropoulou, Senior Consultant Breast Surgical Oncologist at Hospital São Francisco Xavier, shared a post on LinkedIn:
“It was yesterday
International Clinical Trials Day
First RCT, James Lind on May 20, 1747Though:
Despite representing 42% of all cancer patients, adults over 70 make up only 24% of participants in FDA-registered trials. This exclusion persists across healthcare, with older adults using most prescription medications yet comprising only 25-40% of clinical trial participants.
Research shows 27% of current trials still use arbitrary age cutoffs that cannot be justified by science.
FDA recommends against upper age limits unless clearly necessary for safety, emphasizing that pharmaceutical companies should include patients over 75 and evaluate medication differences in older populations.
Main question : are the treatments we prescribe to our most vulnerable patients actually tested on them?
More posts featuring Zacharoula Sidiropoulou.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 22, 2025, 17:32
May 22, 2025, 17:25
May 22, 2025, 16:22
May 22, 2025, 15:55